A real-world analysis of nearly 12,000 patients found that esophageal cell collection was successful in 95% of cases, with procedures taking less than two minutes on average.
Abbott has launched a next-generation Oncodetect MRD test that uses whole-genome sequencing to track up to 5,000 patient-specific cancer variants, offering a 30-fold increase in detection sensitivity, according to the company.
Biodesix, in collaboration with Bio-Rad and Thermo Fisher Scientific, is advancing decentralized tumor-informed and tumor-naïve MRD assays designed for clinical labs, with validation underway at Memorial Sloan Kettering Cancer Center.
Delve Bio has launched Delve Detect Plasma, a blood-based mNGS assay capable of detecting over 68,000 pathogens from a single blood draw, with next-day results.
Read More
Mayo Clinic Laboratories and Pathology Asia Holdings have announced a strategic investment to expand regional access to molecular and genomic diagnostics in Southeast Asia, Australia, and New Zealand.
Read More
UNC and Tulane researchers have developed a CRISPR-based microfluidic assay that identifies 15 nontuberculous mycobacteria species directly from clinical specimens in 3.5 hours, with over 97% sensitivity, according to a recent study.
Read More
A multicenter study led by Children’s Hospital Colorado finds that skin biopsy fibroblast assays can help diagnose primary mitochondrial diseases, potentially reducing the need for invasive muscle and liver biopsies.
Read More
The new testing solution integrates ongoing data reanalysis to re-evaluate variants as clinical gene-disease knowledge expands.
Read More
As molecular diagnostics expand what laboratories can detect, laboratories are placing greater emphasis on matching the breadth of testing to the patient and how the results will be used.
Read More
A new federal directive tasks HHS with launching rapid diagnostic R&D for vector-borne diseases, emphasizing decentralized molecular testing as part of a broader strategy to improve local pathogen surveillance.
Read More
10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.
Read More
Roche Diagnostics has supplied two molecular testing systems and is training laboratory staff in the Democratic Republic of Congo to expand PCR testing capacity for Bundibugyo virus amid rising Ebola testing demand.
Read More
Cerenome has launched two CSF-based molecular profiling tests for CNS cancers, offering DNA and RNA sequencing panels to evaluate primary, metastatic, and hematologic malignancies in the central nervous system.
Read More
Baylor Genetics has been named lead sequencing provider for Florida’s five-year Sunshine Genetics Pilot, which will use whole-genome sequencing to screen newborns for nearly 900 genetic conditions statewide.
Read More
A peer-reviewed study found that Olink proximity extension assay technology correlates with ELISA for measuring endothelin-1 in coronary artery plasma, supporting its use for high-throughput proteomics in clinical research.
Read More
Pillar Biosciences has introduced the oncoReveal Myeloid v2 Panel, expanding its NGS assay from 58 to 80 genes and enhancing FLT3-ITD detection while maintaining existing laboratory workflows.
Read More
Researchers from the PRECISE-SG100K study have identified over 2,500 new genetic-protein associations by analyzing data from 10,000 participants, advancing biomarker discovery in large-scale, multi-ethnic cohorts.
Read More
Renew Biotechnologies and Mayo Clinic have partnered to evaluate NeuroLens, a cfDNA-based test, for monitoring central nervous system injury and disease progression in multiple sclerosis and related neuroimmunologic conditions.
Read More